Bannerbild German Brest Group

November 2018: Exploratory analysis on obese breast cancer patients from the PANTHER trial


Further results from the prospective PANTHER trial focused on obese breast cancer patients treated with adjuvant tailored dose-dense chemotherapy versus standard treatment has been published in the Annals of Oncology.

An exploratory analysis of tailored dosing in the PANTHER trial demonstrated that obese patients (BMI≥30) treated with tailored dose-dense chemotherapy had improved breast cancer relapse-free survival (BCRFS) compared to non-obese ones (BMI<30) (HR = 0.51 [95% CI 0.30-0.89]; p=0.02). Furthermore, the tailored dose-dense chemotherapy was associated with improved BCRFS compared to standard anthracycline/taxane containing regimen only in obese patients (HR=0.49 [95%CI 0.26-0.90]; p=0.022, test for interaction p=0.175). There were no differences in terms of toxicity between the BMI groups. Hence, the use of tailored dose-dense regimen as adjuvant chemotherapy can potentially improve outcomes in obese patients without increasing toxicity and should be pursued in further clinical studies.

Matikas A, Foukakis T, Moebus V, Greil R, Bengtsson NO, Steger GG, Untch M, Johansson H, Hellström M, Malmström P, Gnant M, Loibl S, Bergh J. Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: Further results from the prospective PANTHER study with focus on obese patients. Ann Oncol. 2018 Oct 24 [Epub ahead of print].

Link in PubMed


  • 04.06.2018 ASCO: GeparNuevo Presentation

    GeparNuevo Results of primary objective were presented at ASCO 2018: Durvalumab increases the pCR rate in TNBC patients.

    Mehr ...
  • 31.05.2018 Paper of the month: elderly women and neoadjuvant chemotherapy

    A pooled analysis using data from eight GBG trials (GeparDuo, GeparTrio pilot and main, GeparQuattro, AGO-1, PREPARE, TECHNO; GeparQuinto) that aimed to help selecting appropriately the elderly women who would benefit from neoadjuvant chemotherapy has been published in the Oncotarget.

    Mehr ...
  • 30.04.2018 Paper of the month: survival analysis of the GeparQuinto trial

    We are delighted to inform you that the long-term survival analysis of the neoadjuvant GeparQuinto (GBG 44) phase III trial has been published in the Journal of Clinical Oncology.

    Mehr ...
  • 30.03.2018 Paper of the month: March 2018

    An analysis of 802 women with triple-negative breast cancer (TNBC) from the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) and GeparSixto (GBG 66) trial that investigated the association between the age at TNBC diagnosis and the presence of pathogenic germline BRCA1/2 mutations has been published in the BMC Cancer.

    Mehr ...

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd